번호가 부여된 미생물 표준물질 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the enumerated microbial reference materials market is projected to be USD 164.99 million in 2025, USD 177.60 million in 2026, and reach USD 263.01 million by 2031, growing at a CAGR of 8.17% from 2026 to 2031.

This report is Segmented by Product Type (Bacterial Enumerated Reference Materials, Fungal Enumerated Reference Materials, and Others), Form (Lyophilized, Frozen, and Others), End-User (Pharmaceutical and Biotechnology Companies, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Enumerated Microbial Reference Materials Market Trends and Insights

Expanding Biopharmaceutical Release and Method-Validation Workflows

The enumerated microbial reference materials market is gaining support from the way biologics manufacturing raises the frequency and criticality of microbiology checks. Cell therapies, gene therapies, antibody-drug conjugates, and other high-value products require tighter environmental monitoring, stronger in-process control, and faster release support than many traditional operations. Short-life products also leave less time for extended contamination testing, which makes validated rapid methods more relevant in release workflows. That shift does not reduce the need for quantified challenge organisms, because each method qualification still depends on defined positive controls and repeatable organism loads. The same facility can therefore continue its legacy compendial testing while also validating new platforms, which creates overlapping points of consumption for the enumerated microbial reference materials market. Each added GMP site or added biologics line also acts as a separate procurement node, so demand expands through new testing locations rather than only through larger wallet share at existing accounts.

Tightening Pharmacopoeial and ISO Traceability Requirements

The enumerated microbial reference materials market is also being lifted by a broad compliance refresh across microbiology standards. USP posted the official revision notice for rapid microbiological methods in 2025, and that change gave laboratories a clearer compendial path for contamination detection in short-life products. Charles River also described how USP formalized the use of ATP-bioluminescence methods and linked those workflows to validated reference microorganism preparations. The practical effect is a steady renewal cycle in which the enumerated microbial reference materials market benefits from repeat qualification work, stronger traceability expectations, and growing demand for audit-ready certificates that can move across internal quality systems with less manual reconciliation.

High Cold-Chain and Stability Assurance Costs

The enumerated microbial reference materials market remains exposed to basic logistics risk because viability and quantitative accuracy can fall quickly when storage conditions drift. Frozen and liquid formats often need continuous low-temperature control from production through delivery, which raises shipping complexity for global customers. That issue becomes more visible in regions where import handling is slower or ultra-cold infrastructure is less dependable. As a result, the enumerated microbial reference materials market can lose some speed when product format, freight reliability, and destination infrastructure do not align with the buyer's validation needs.

Other drivers and restraints analyzed in the detailed report include:

1. Rising Use of Rapid Microbial Methods in Routine QC
2. Growth in Outsourced Microbiology Testing and Reference Lab Networks
3. Fragmented Pharmacopoeial Acceptance, Limited Panel Availability, and Slow Qualification Cycles

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Bacterial enumerated materials held 55.33% of the enumerated microbial reference materials market share in 2025, which reflects their central role in routine compendial microbiology programs. Species such as Bacillus subtilis, Staphylococcus aureus, and Pseudomonas aeruginosa remain embedded in everyday method suitability and quality control work across established USP-linked workflows. In this part of the enumerated microbial reference materials market, differentiation comes more from format, enumeration accuracy, and speed of use than from organism novelty.

Mixed microbial enumerated materials are forecasted to grow at 8.24% CAGR from 2026 to 2031, making them the fastest-expanding product type in the enumerated microbial reference materials market. Their growth reflects wider use of multi-organism challenges in rapid method validation, environmental monitoring qualification, and broader surveillance settings. Buyers increasingly want panels that better match real testing conditions instead of validating each step with single-organism preparations only. ISO 17034 readiness also matters across the product mix, because it helps established suppliers defend share when regulated buyers narrow approved vendor lists in the enumerated microbial reference materials industry.

Complete Report Scope:

• By Product Type
  • Bacterial Enumerated Reference Materials
  • Fungal Enumerated Reference Materials
  • Mixed Microbial Enumerated Reference Materials
  • Other Microbial Enumerated Reference Materials
• By Form
  • Lyophilized
  • Frozen
  • Liquid
  • Other Forms
• By End-User
  • Pharmaceutical and Biotechnology Companies
  • Clinical and Diagnostic Laboratories
  • Academic and Research Institutes
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 46.32% of the enumerated microbial reference materials market share in 2025, which kept it in the leading regional position. That position rests on the density of FDA-regulated pharmaceutical production and the close link between laboratory practice and USP notices that became official in 2025. When microbiology chapters are revised, laboratories in this region usually have to update validation files, retrain staff, and confirm that reference materials still fit their approved procedures. The enumerated microbial reference materials market therefore benefits from recurrent documentation work, not only from rising production volume. Europe remained the second-largest regional block, supported by large biopharmaceutical manufacturing centers and a strong compliance culture in pharmaceutical quality systems.

European demand is shaped by both established production clusters and active pharmacopoeial governance. France's updated good manufacturing practice guidance published by ANSM in June 2024 reinforced the role of pharmacopoeial reference expectations in pharmaceutical compounding and related quality activities. That matters because the region often moves early on documentation discipline and validation formalization, which supports steady demand for traceable organism preparations. The enumerated microbial reference materials market in Europe therefore remains anchored by buyers that prioritize lot traceability, qualified suppliers, and evidence that can support inspections across several countries.

Asia-Pacific is forecasted to grow at 10.21% CAGR from 2026 to 2031, making it the fastest-growing regional segment in the enumerated microbial reference materials market. The region's momentum comes from expanding biologics capacity, stronger quality infrastructure, and a broader shift from basic production toward more demanding therapies and testing workflows. As a result, the enumerated microbial reference materials market in Asia-Pacific is expanding through both sophistication gains and wider manufacturing scale. The Middle East and Africa and South America remain smaller in absolute terms, but both add incremental opportunities for the enumerated microbial reference materials market. Gulf manufacturing investment is lifting the need for GMP-aligned microbiology controls, while South Africa continues to act as a regional testing anchor. In South America, Brazil and Argentina continue to matter because established pharmaceutical production creates recurring demand for qualified microbiology inputs. The Eurasian Economic Union's 2024 pharmacopoeial update on microbiological purity requirements also points to gradual convergence with broader international practice, which may ease market entry over time for suppliers serving that wider region.

1. ATCC
2. Beckton Dickinson
3. bioMerieux
4. Bio-Rad Laboratories
5. Charles River
6. Danaher
7. Fera Science Limited
8. Hardy Diagnostics
9. HyServe GmbH and Co. KG
10. LGC Group
11. Liofilchem S.r.l.
12. Merck
13. Microbiologics, Inc.
14. R-Biopharm
15. Revvity, Inc.
16. Sartorius
17. Southern Group Laboratory Ltd.
18. TCS Biosciences Ltd.
19. Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Expanding Biopharmaceutical Release and Method-Validation Workflows
  • 4.2.2 Tightening Pharmacopoeial and ISO Traceability Requirements
  • 4.2.3 Rising Use of Rapid Microbial Methods in Routine QC
  • 4.2.4 Growth in Outsourced Microbiology Testing and Reference Lab Networks
  • 4.2.5 Regulatory Push for Digital Certificates of Analysis and Audit-Ready Lot Traceability
  • 4.2.6 Regionalization of Qualified Reference Material Supply Chains
• 4.3 Market Restraints
  • 4.3.1 High Cold-Chain and Stability Assurance Costs
  • 4.3.2 Fragmented Pharmacopoeial and National Acceptance Requirements
  • 4.3.3 Limited Availability of Truly Quantified Multi-Organism Reference Panels
  • 4.3.4 Slow Customer Qualification Cycles for Regulated Manufacturing Sites
• 4.4 Supply/Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Bacterial Enumerated Reference Materials
  • 5.1.2 Fungal Enumerated Reference Materials
  • 5.1.3 Mixed Microbial Enumerated Reference Materials
  • 5.1.4 Other Microbial Enumerated Reference Materials
• 5.2 By Form
  • 5.2.1 Lyophilized
  • 5.2.2 Frozen
  • 5.2.3 Liquid
  • 5.2.4 Other Forms
• 5.3 By End-User
  • 5.3.1 Pharmaceutical and Biotechnology Companies
  • 5.3.2 Clinical and Diagnostic Laboratories
  • 5.3.3 Academic and Research Institutes
  • 5.3.4 Other End Users
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, Recent Developments)
  • 6.3.1 ATCC
  • 6.3.2 Becton, Dickinson and Company
  • 6.3.3 bioMerieux SA
  • 6.3.4 Bio-Rad Laboratories, Inc.
  • 6.3.5 Charles River Laboratories International, Inc.
  • 6.3.6 Danaher Corporation
  • 6.3.7 Fera Science Limited
  • 6.3.8 Hardy Diagnostics
  • 6.3.9 HyServe GmbH and Co. KG
  • 6.3.10 LGC Limited
  • 6.3.11 Liofilchem S.r.l.
  • 6.3.12 Merck KGaA
  • 6.3.13 Microbiologics, Inc.
  • 6.3.14 R-Biopharm AG
  • 6.3.15 Revvity, Inc.
  • 6.3.16 Sartorius AG
  • 6.3.17 Southern Group Laboratory Ltd.
  • 6.3.18 TCS Biosciences Ltd.
  • 6.3.19 Thermo Fisher Scientific Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment